Content by National Cancer Centre Singapore
|2 min read
Liver Cancer Adjuvant Immunotherapy Improved Survival in Phase 3 Trial
Some 70–90 percent of patients with hepatocellular carcinoma experience cancer recurrence after curative treatmentPage 1 of 1




